This review aims to evaluate the potential of irisin, whether exercise-induced or administered as a recombinant protein, as a therapeutic agent for mitigating the risk of MetS that arises secondary to oestradiol withdrawal in postmenopausal women. Here, FNDC5 is linked to metabolic syndrome.